Skip to main content
Premium Trial:

Request an Annual Quote

Clinical Reference Lab to Validate Nuclea's Assays

NEW YORK (GenomeWeb) – Nuclea Biotechnologies today said it has inked an agreement with Clinical Reference Laboratory to validate three of Nuclea's tests.

As part of the deal, CRL will initially validate Nuclea's Oncogene Science 159 gene-based prostate cancer monitoring test. Nuclea obtained the test when it acquired Wilex, the wholly owned subsidiary of Wilex AG, in September.

CRL will also validate Nuclea's Nuvera breast cancer assay and its US Food and Drug Administration-approved, serum HER-2/neu blood test.

Nuclea will clinically interpret test results and market and distribute the tests. The Pittsfield, Mass.-based company said that it anticipates the Nuvera and Oncogene Science assays to be available in the next 60 days, while the HER-2/neu assay will be launched later this year.

Financial and other terms of the deal were not disclosed.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more